I have a theory, comments/discussion most welcome.
I've been a holder of a decent size of Biocurex shares for a few years now. I rarely post - in fact, I think I only ever posted once or twice a couple of years ago! But I have always kept a close eye on the company and its developments and remain totally committed, supportive and excited.
It's struck me as very strange that we have had two obvious long-awaited developments that have not materialised. Firstly, the re-listing of the shares onto the OTC-BB or better (AMEX, Nasdaq Small-cap etc) and secondly, further licensing deals following the Abbot coup. Both events were forecast by management on more than one occasion these last couple of years. Obviously things always seem to take much longer to pan out for a multitude of reasons but it seems here to be taking an awfully much longer time than would be considered reasonable. I am sure most fellow shareholders would agree with me.
I am beginning to think that there may be more going on here than is readily apparent. These are my thoughts for what they're worth :
Remember that Biocurex awarded Abbot a semi-exclusive license so that they could pursue the same type of deal with other large and medium-sized companies they said then that they were well down the road in negotiating with. Now we all know that a lot of time has passed since we signed up with Abbot and no other licencing deals have been signed. Hmmmm. And also, despite noises to the contrary on several occasions, we're still on the pinks. Is it possible to conclude, I wonder, that the feedback from Abbot is so good to the extent that Abbot don't want their competitors to get in on this technology and they've basically signalled to Biocurex : 'give us some time to fully test this, step back from signing any other deals for an agreed period, then we'll upgrade our deal with you to a fully exclusive license for which we'll pay you $x million upfront and a more generous royalty going forward'. The $x million upfront would satisfy the conditions for an AMEX or other share listing and/or facilitate an institutional placing at a greatly enhanced price level on the back of this great deal. So, two birds hit with one stone and this might explain why both overdue developments haven't materialised.
Do any of you long-termers here buy this possible explanation? From where I stand it certainly appears plausible, but hey, what do I know?!! Comments/discussion most welcome, thanks.
All the best,
merovingian
